Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TPST-002
- Development stage
- Preclinical
- Lead developer
- Tempest Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
TPST-002 is a preclinical-stage in vivo chimeric antigen receptor T-cell (CAR-T) therapy being developed by Tempest Therapeutics for the treatment of solid tumors. The therapy is built on Tempest's proprietary CD7-targeted mRNA lipid nanoparticle (CD7-tLNP) platform, which is engineered to deliver CAR-encoding mRNA directly to both CD4+ and CD8+ T cells in vivo. By targeting CD7, the delivery system facilitates rapid cellular internalization and transient CAR expression, bypassing the complex ex vivo manufacturing and lymphodepletion conditioning required for conventional autologous CAR-T therapies. TPST-002 is designed to target undisclosed tumor-associated antigens to treat various solid tumors.
- Other names
- TPST 002TPST002TPST-002
02
Targets
CD7 (CD7 antigen)
Beyond the preview
Go deeper on TPST-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TPST-002.